StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
3309.HK$1.08+1.89%
Fair $1.08+0.0%

3309.HK

C-MER Medical Holdings Limited

Healthcare / Medical Care FacilitiesHKSE

$1.08

+0.02 (+1.89%)

Fairly Valued+0.0%Fair Value $1.08Fund rank 34/100 · Data gapFallback financials|
SA 45/C
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $202.3M · quality 71.3/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 65/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

45/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists.
Thesis & Journal · 3309.HKLocal privado en este navegador · C-MER Medical Holdings Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.3B

P/E

13.5x

↓

EV/EBITDA

3.6x

↓

ROE

5.7%

↑

Gross Margin

31.0%

↓

Debt/Equity

0.24

↑
52-Week Range$1
$1$2

TradingView lightweight chart

3309.HK price, volumen y niveles de valoración

Último $1.080Periodo -78.9%
Fair value: $1.080

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+4.0%

FCF CAGR

+40.1%

FCF margin

10.4%

FCF / Net income

2.02x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.95B · net income $100.4M · FCF $202.3M

2022-FY → 2025-FY

Gross margin

31.0%+5.2% pts

Operating margin

6.9%+7.8% pts

Net margin

5.2%+6.4% pts

FCF margin

10.4%+6.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.95B$1.95B$1.91B$1.92B$1.73B
Net Income$100.4M$100.4M$-135.2M$62.0M$-21.9M
EBITDA$378.6M$378.6M$278.9M$363.4M$232.5M
EPS0.080.08-0.110.05-0.02
Gross Margin31.0%31.0%27.6%32.2%25.9%
Operating Margin6.9%6.9%2.8%6.2%-0.9%
Net Margin5.2%5.2%-7.1%3.2%-1.3%
Balance Sheet
Debt/Equity0.240.240.250.200.24
Current Ratio1.431.43———
Cash Flow
Free Cash Flow$202.3M$202.3M$123.6M$245.3M$73.6M
Returns
ROE5.7%5.7%-7.7%3.4%-1.2%
Valuation
P/E13.5013.50—67.81—
EV/EBITDA3.653.658.4111.1625.80
P/B0.730.731.332.283.32
Growth & Yield
Revenue Growth1.8%1.8%-0.6%11.1%—
EPS Growth176.0%176.0%-321.9%379.1%—
Dividend Yield1.8%1.8%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

4.8%

fácil

EPS terminal req.

$0.10

Spread vs growth

171.2%

5Y implied EPS CAGR

6.8%

razonable

EPS terminal req.

$0.12

Spread vs growth

169.2%

10Y implied EPS CAGR

8.4%

razonable

EPS terminal req.

$0.19

Spread vs growth

167.6%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -33.9%

Total return

-33.9%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.11 → 0.08

Residual

-35.7%

EPS growthn/d
Multiple reratingn/d
Dividend+1.8%
Residual / FX / buybacks / cross-term-35.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.